SamaCare’s 2022 Specialty Provider Market Access Survey Specialty Focus: Medical Oncology & Hematology and Oncology
The SamaCare Team
Key Takeaways
Overall, oncology practices are more confident in their efficiency navigating the prior authorization process. They were also less likely to perceive a growth in the PA burden — possibly because oncologists face some of the most arduous PA processes already.
While oncology practices are more likely to engage with market access teams than other specialities, only 44% of practices indicate that market access teams are “often” effective at troubleshooting prior authorization issues while 66% indicate market access teams are only “occasionally”, “rarely”, or “never” effective.
80% of oncologists surveyed indicate the prior authorization process has a “somewhat negative” impact on patient outcomes. While somewhat lower than other specialties, this 80% majority is nonetheless a stark statistic in the context of cancer care.
Complete Survey Results
[Q1]: How efficient is your practice at navigating the prior authorization process for physician-administered medications?
[Q2]: To what extent do you agree or disagree with the following statement: Consistent prior authorization denials and/or delays for a specific drug would impact my likelihood to prescribe this medication if there was an equally effective alternative in the market.
[Q3]: Over the past 12 months, how has your practice's experience with prior authorizations changed?
[Q4]: Overall, how aware are you of market access and reimbursement services offered by drug companies?
[Q5]: Overall, how often does your practice engage the assistance of drug companies in navigating the prior authorization process for their drugs?
[Q6]: How often are drug companies effective at helping your practice troubleshoot prior authorizations?
[Q7]: How does the prior authorization process impact patient care?
[Q8]: How do prior authorization delays or denials impact patients' likelihood to adhere to a treatment plan?
[Q9]: How does the prior authorization process impact patient outcomes?
[Q10]: When a patient of yours is on a branded medication, how often does that patient get signed up for any patient assistance services offered by the drug company (e.g., copay or financial assistance, drug education, nurse support, etc.)
Key Takeaways
Overall, oncology practices are more confident in their efficiency navigating the prior authorization process. They were also less likely to perceive a growth in the PA burden — possibly because oncologists face some of the most arduous PA processes already.
While oncology practices are more likely to engage with market access teams than other specialities, only 44% of practices indicate that market access teams are “often” effective at troubleshooting prior authorization issues while 66% indicate market access teams are only “occasionally”, “rarely”, or “never” effective.
80% of oncologists surveyed indicate the prior authorization process has a “somewhat negative” impact on patient outcomes. While somewhat lower than other specialties, this 80% majority is nonetheless a stark statistic in the context of cancer care.
Complete Survey Results
[Q1]: How efficient is your practice at navigating the prior authorization process for physician-administered medications?
[Q2]: To what extent do you agree or disagree with the following statement: Consistent prior authorization denials and/or delays for a specific drug would impact my likelihood to prescribe this medication if there was an equally effective alternative in the market.
[Q3]: Over the past 12 months, how has your practice's experience with prior authorizations changed?
[Q4]: Overall, how aware are you of market access and reimbursement services offered by drug companies?
[Q5]: Overall, how often does your practice engage the assistance of drug companies in navigating the prior authorization process for their drugs?
[Q6]: How often are drug companies effective at helping your practice troubleshoot prior authorizations?
[Q7]: How does the prior authorization process impact patient care?
[Q8]: How do prior authorization delays or denials impact patients' likelihood to adhere to a treatment plan?
[Q9]: How does the prior authorization process impact patient outcomes?
[Q10]: When a patient of yours is on a branded medication, how often does that patient get signed up for any patient assistance services offered by the drug company (e.g., copay or financial assistance, drug education, nurse support, etc.)
SamaCare’s 2022 Specialty Provider Market Access Survey Specialty Focus: Medical Oncology & Hematology and Oncology
The SamaCare Team
Key Takeaways
Overall, oncology practices are more confident in their efficiency navigating the prior authorization process. They were also less likely to perceive a growth in the PA burden — possibly because oncologists face some of the most arduous PA processes already.
While oncology practices are more likely to engage with market access teams than other specialities, only 44% of practices indicate that market access teams are “often” effective at troubleshooting prior authorization issues while 66% indicate market access teams are only “occasionally”, “rarely”, or “never” effective.
80% of oncologists surveyed indicate the prior authorization process has a “somewhat negative” impact on patient outcomes. While somewhat lower than other specialties, this 80% majority is nonetheless a stark statistic in the context of cancer care.
Complete Survey Results
[Q1]: How efficient is your practice at navigating the prior authorization process for physician-administered medications?
[Q2]: To what extent do you agree or disagree with the following statement: Consistent prior authorization denials and/or delays for a specific drug would impact my likelihood to prescribe this medication if there was an equally effective alternative in the market.
[Q3]: Over the past 12 months, how has your practice's experience with prior authorizations changed?
[Q4]: Overall, how aware are you of market access and reimbursement services offered by drug companies?
[Q5]: Overall, how often does your practice engage the assistance of drug companies in navigating the prior authorization process for their drugs?
[Q6]: How often are drug companies effective at helping your practice troubleshoot prior authorizations?
[Q7]: How does the prior authorization process impact patient care?
[Q8]: How do prior authorization delays or denials impact patients' likelihood to adhere to a treatment plan?
[Q9]: How does the prior authorization process impact patient outcomes?
[Q10]: When a patient of yours is on a branded medication, how often does that patient get signed up for any patient assistance services offered by the drug company (e.g., copay or financial assistance, drug education, nurse support, etc.)
Key Takeaways
Overall, oncology practices are more confident in their efficiency navigating the prior authorization process. They were also less likely to perceive a growth in the PA burden — possibly because oncologists face some of the most arduous PA processes already.
While oncology practices are more likely to engage with market access teams than other specialities, only 44% of practices indicate that market access teams are “often” effective at troubleshooting prior authorization issues while 66% indicate market access teams are only “occasionally”, “rarely”, or “never” effective.
80% of oncologists surveyed indicate the prior authorization process has a “somewhat negative” impact on patient outcomes. While somewhat lower than other specialties, this 80% majority is nonetheless a stark statistic in the context of cancer care.
Complete Survey Results
[Q1]: How efficient is your practice at navigating the prior authorization process for physician-administered medications?
[Q2]: To what extent do you agree or disagree with the following statement: Consistent prior authorization denials and/or delays for a specific drug would impact my likelihood to prescribe this medication if there was an equally effective alternative in the market.
[Q3]: Over the past 12 months, how has your practice's experience with prior authorizations changed?
[Q4]: Overall, how aware are you of market access and reimbursement services offered by drug companies?
[Q5]: Overall, how often does your practice engage the assistance of drug companies in navigating the prior authorization process for their drugs?
[Q6]: How often are drug companies effective at helping your practice troubleshoot prior authorizations?
[Q7]: How does the prior authorization process impact patient care?
[Q8]: How do prior authorization delays or denials impact patients' likelihood to adhere to a treatment plan?
[Q9]: How does the prior authorization process impact patient outcomes?
[Q10]: When a patient of yours is on a branded medication, how often does that patient get signed up for any patient assistance services offered by the drug company (e.g., copay or financial assistance, drug education, nurse support, etc.)
